Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action (Forsteo)

Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A Two-year Open-label Single-arm Study of Teriparatide in Secondary Care

Previously the approach to treatment of osteoporosis has been to use medications which prevent excessive resorption of bone. More recently medications that build up new bone, i.e. anabolic treatments, have been, and are being, developed. The investigators would like to develop a strategy for evaluating the effectiveness of anabolic therapies by studying a currently available therapy (teriparatide). This strategy could then be used to assess new anabolic treatments as they are developed for use in humans.

The aims of this study are 1) to fully describe the changes in bone turnover in response to teriparatide by biochemical marker type and by time; 2) to fully describe the changes in bone mineral density (BMD) in response to teriparatide by site, bone compartment and time.

If this study is able to identify an early response to treatment, then this will help speed up drug development in this area, by allowing the identification of promising new anabolic drugs and enabling us to understand their mechanism of action. This will benefit the investigators patients as the investigators will have a better understanding of how these drugs work.

Study Overview

• Status: Completed
• Conditions: Osteoporosis
• Intervention / Treatment: Drug: Teriparatide

• Study Type: Interventional
• Enrollment (Actual): 19
• Phase: Phase 4

Contacts and Locations

Study Locations

• United Kingdom
  • South Yorkshire
    • Sheffield, South Yorkshire, United Kingdom, S5 7AU
      • Sheffield Teaching Hospitals NHS Foundation Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 84 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

Subjects must:

• Have a bone mineral density T-score (at the lumbar spine or total hip) of less than or equal to -2.5
• Be female
• Be at least 5 years post menopausal (more than 5 years since their last menstrual period) but <85 years old.
• Be ambulatory
• Be able and willing to participate in the study and provide written informed consent
• Have a serum 25(OH)2 vitamin D3 >50 nmol/L (after vitamin D3 loading)

Exclusion Criteria

Patients will not be admitted to the study if they exhibit any of the following:

• Evidence of a clinically significant organic disease which could prevent the patient from completing the study
• A body mass index less than 18 or greater than 35
• Abuse of alcohol or use illicit drugs (information obtained from medical history) or who consumed more than 4 servings of any alcoholic beverage one day prior to the visit (i.e., subjects who might be binge drinkers)
• Any history of cancer within the past 5 years excluding skin cancer non melanomas
• Any history of ongoing conditions or diseases known to cause abnormalities of calcium metabolism or skeletal health including Paget's disease of bone
• Chronic renal disease (as defined by an estimated glomerular filtration rate of ≤ 30mL/min)
• Acute or chronic hepatic disease
• Malabsorption syndromes
• Hyperthyroidism as manifested by TSH outside the lower limit of the normal range
• Hyperparathyroidism
• Hypocalcemia or hypercalcemia
• Osteomalacia
• Cushing's syndrome
• Current use of glucocorticoid therapy
• A corrected serum calcium less than 2.2 mmol/L and a PTH above 100 ng/L (that persists after testing and treatment for vitamin D deficiency)
• A history of any known condition that would interfere with the assessment of DXA at either lumbar spine or femoral neck
• Markedly abnormal clinical laboratory parameters that are assessed as clinically significant by the investigator
• Any previous use of bisphosphonate
• Use any of the following medications within 12 months of starting study drug
• Any fluoride with the exception of use for oral hygiene
• Strontium Ranelate
• Other bone agents (e.g. SERM, isoflavones, HRT)
• Participation in another clinical trial involving active therapy 3 months prior to enrolment
• Less than 5 years since menopause
• Bilateral fractures in the measurement regions (hip, tibia and forearm)
• Recent fracture within the last 12 months
• Prior radiation therapy which may involve the skeleton
• Hypersensitivity to teriparatide or any of its excipients
• Unexplained elevations of alkaline phosphatase
• Any known contraindication to the use of teriparatide

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Volumetric bone mineral density (BMD) of the lumbar spine (mg hydroxyapatite/cm3)	Change in volumetric BMD of the lumbar spine (vertebrae L1-3) (mg hydroxyapatite/cm3) measured by quantitative computed tomography (QCT) from 0 to 104 weeks treatment.	0 to 104 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lumbar spine, total hip and whole body bone mineral density (g/cm2)	Changes in lumbar spine, total hip and whole body bone mineral density (g/cm2) measured by dual x-ray absorptiometry (DXA) from 0 to 104 weeks.	0 to 104 weeks
Biochemical markers of bone turnover	Changes in biochemcial markers of bone turnover (OC, PINP, bone ALP, urinary NTX, serum CTX, sclerostin, DKK-1) from 0 to 104 weeks.	0 to 104 weeks
Distal tibia and radius volumetric body bone mineral density (BMD) (mg hydroxyapatite/cm3)	Changes in distal tibia and radius volumetric bone mineral density (mg hydroxyapatite/cm3) measured by High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) from 0 to 104 weeks.	0 to 104 weeks

Collaborators and Investigators

• Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
• Collaborators: National Institute for Health Research, United Kingdom
• Investigators: Study Director: Richard Eastell, MD, FRCP, FRCPath, FMedSci, University of Sheffield; Principal Investigator: Jennifer Walsh, PhD MRCP, Sheffield Teaching Hospitals NHS Foundation Trust; Principal Investigator: Eugene McCloskey, MD, FRCPI, University of Sheffield; Principal Investigator: Nicola Peel, DM FRCP, Sheffield Teaching Hospitals NHS Foundation Trust; Principal Investigator: Angela Rogers, BSc (Hons), PhD, MCSP, University of Sheffield; Principal Investigator: Margaret Paggiosi, Bsc (Hons), PhD, MICR, Sheffield Teaching Hospitals NHS Foundation Trust; Principal Investigator: Lang Yang, PhD CSci, University of Sheffield; Principal Investigator: David Hughes, BMedSci MBChB PhD FRCPath, Sheffield Teaching Hospitals NHS Foundation Trust; Principal Investigator: Mark Wilkinson, PhD, FRCS (Tr&Orth), University of Sheffield

Publications and helpful links

General Publications

• Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1302-1309. doi: 10.1210/jc.2017-00283.

Study record dates

Study Major Dates

• Study Start: January 1, 2011
• Primary Completion (Actual): August 1, 2015
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: February 4, 2011
• First Submitted That Met QC Criteria: February 9, 2011
• First Posted (Estimated): February 10, 2011

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 15, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Osteoporosis; Teriparatide; Forsteo
• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Bone Diseases, Metabolic; Nutritional and Metabolic Diseases; Osteoporosis; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptide Hormones; Peptides; Amino Acids, Peptides, and Proteins; Parathyroid Hormone; Teriparatide
• Other Study ID Numbers: STH15466; 2010-021009-19 (EudraCT Number)